Key Events This Week
Feb 9: Downgrade to Sell by MarketsMOJO announced
Feb 13: Q3 FY26 results reveal revenue decline but stable margins
Feb 13: Week closes at Rs.115.20 (-1.66%)

Smruthi Organics Q3 FY26: Revenue Decline Weighs on Performance Despite Margin Resilience
2026-02-13 13:53:49Smruthi Organics Ltd., a micro-cap pharmaceuticals and biotechnology company with a market capitalisation of ₹137.00 crores, reported a challenging third quarter for FY2026, with net profit declining 32.04% quarter-on-quarter to ₹1.40 crores from ₹2.06 crores in Q2 FY26. On a year-on-year basis, the company managed a modest 5.41% decline from ₹1.48 crores in Q3 FY25. The stock traded at ₹117.00 on February 13, 2026, down 0.85% from the previous close, reflecting investor concerns over the sequential revenue contraction that has pressured profitability.
Read full news article
Smruthi Organics Ltd Downgraded to Sell Amid Technical Weakness and Long-Term Underperformance
2026-02-09 08:15:00Smruthi Organics Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 6 February 2026. This revision reflects a combination of deteriorating technical indicators, subdued long-term financial trends, and valuation concerns despite some recent positive quarterly performance.
Read full news article









